AbbVie to buy drug developer Cerevel for $8.7 billion AbbVie is to buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its … Business • 07 Dec
AbbVie to buy ImmunoGen to boost cancer drug portfolio AbbVie said today it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments. Business • 30 Nov
Allergan's Westport Botox plant makes $1.5bn in profits Westport's status as the global production capital of Botox was further enhanced last year as world wide sales of the treatment from a local manufacturing … Business • 29 Nov
AbbVie to invest €60m in Cork, creating 70 jobs Biopharma company AbbVie is to invest €60m in an expansion of its plant in Carrigtwohill in Co Cork, creating 70 jobs. Business • 21 Sep 22
AbbVie's 'precautionary' court action against Revenue Pharmaceutical giant AbbVie has brought a "precautionary" High Court action against Revenue arising from a €587m tax bill served on it after it acquired Allergen. Business • 19 Jan 21
Buffett's Berkshire bets on Big Pharma Warren Buffett's Berkshire Hathaway said it has begun investing in the stocks of four large drugmakers, betting on an industry that could benefit when the … Business • 17 Nov 20
UDG reinstates financial guidance, names new chair UDG Healthcare has reinstated its financial guidance for 2020, with the group forecasting a 7.1-11.2% fall in earnings year-on-year. Business • 05 Aug 20
AbbVie reports loss as Covid-19 hits Botox sales Drugmaker AbbVie has today reported a loss in the second quarter, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion … Business • 31 Jul 20
EU conditionally approves Allergan takeover by Abbvie The European Commission has approved US drugmaker AbbVie's planned $63 billion acquisition of Dublin headquartered Botox-maker Allergan, subject to conditions. Business • 10 Jan 20
Allergan shareholders give AbbVie takeover green light Shareholders at Dublin headquartered Botox-maker Allergan have strongly backed its $63bn takeover by US pharmaceutical company AbbVie. Business • 14 Oct 19
AbbVie to buy Botox-maker Allergan in $63 billion deal AbbVie said today it would buy Botox-maker Allergan in a cash-and-stock deal for about $63 billion to add fast-growing therapeutic businesses such as medical aesthetics … Business • 25 Jun 19
Union warns AbbVie of possible action escalation Management at global pharmaceutical company AbbVie have been urged to engage in talks with SIPTU or face an escalation in industrial action in the New … Munster • 11 Dec 17
Work stoppage takes place at Cork AbbVie plant Pickets have been placed again by SIPTU members on a county Cork bio-pharmaceutical plant in a dispute over union recognition. Munster • 07 Dec 17
Pickets placed on Cork biopharmaceutical plant SIPTU members placed pickets on a Co Cork biopharmaceutical plant in a dispute over union recognition. Munster • 14 Nov 17
AbbVie agrees $21 billion Pharmacyclics deal AbbVie is to buy Pharmacyclics for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs. Business • 05 Mar 15
AbbVie beats estimates on higher Humira sales US drugmaker AbbVie today reported a better than expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira. Business • 30 Jan 15
Shire raises guidance again after Q3 earnings jump Pharmaceutical firm Shire has today raised its guidance for full-year earnings. Business • 24 Oct 14
AbbVie turns against $55 billion Shire acquisition AbbVie has pulled the plug on its plan to buy Shire, recommending shareholders vote against the planned $55 billion takeover following new US tax rules. Business • 16 Oct 14
Shire urges AbbVie to proceed with $54bn deal Shire Pharmaceuticals today urged AbbVie to proceed with its agreed $54-billion takeover. Business • 15 Oct 14
Shire formally accepts AbbVie takeover offer Dublin-based Shire Pharmaceuticals has accepted a €40bn takeover bid from US giant AbbVie, the two companies have said. Business • 18 Jul 14
Shire 'ready to accept' latest AbbVie bid Shire succumbed to an increased $53 billion takeover offer from AbbVie this morning, signalling the conclusion to a long-running courtship largely motivated by tax. Business • 14 Jul 14
AbbVie retracts comments in Shire takeover bid AbbVie has been forced to retract comments by its chief executive about shareholder support for its bid for Shire after being caught out by British … Business • 09 Jul 14
AbbVie ups bid for drugmaker Shire to £30 billion AbbVie raised its offer for Shire to £30.1 billion today, hoping to win over its reluctant target after three earlier offers were rejected. Business • 08 Jul 14
Patent win helps Shire as AbbVie plots next move Shire has a new reason to argue it is worth more after a US court backed patent claims on its top-selling drug Vyvanse. Business • 25 Jun 14
Shire flags new drugs in defence to AbbVie Shire has flagged the promise of existing and new drugs as evidence that AbbVie's $46 billion offer undervalued the company. Business • 23 Jun 14
